期刊
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
卷 22, 期 11, 页码 5220-5230出版社
WILEY
DOI: 10.1111/jcmm.13719
关键词
breast cancer; CD44; isobavachalcone; oestrogen receptor alpha; paclitaxel resistance
资金
- project of Science & Technology of Nanjing [YKK14081]
- Natural Science Foundation of Jiangsu Province [BK20150092]
- National Natural Science Foundation of China [81502623]
- Key R & D Special Fund of Jiangsu Province [BE2017611]
Oestrogen receptor (ER) is expressed in approximately 60%-70% of human breast cancer. Clinical trials and retrospective analyses have shown that ER-positive (ER+) tumours are more tolerant to chemotherapeutic drug resistance than ER-negative (ER-) tumours. In addition, isobavachalcone (IBC) is known as a kind of phytoestrogen with antitumour effect. However, the underlying mechanism of IBC in ER+ breast cancer needs to be elucidated further. Our invitro experiments showed that IBC could attenuate 17 beta-estradiol (E-2)-induced paclitaxel resistance and that E-2 could stimulate CD44 expression in ER+ breast cancer cells but not in ER- cells. Meanwhile, E-2 could promote ER alpha expression to render ER+ breast cancer cells resistant to paclitaxel. Furthermore, we established paclitaxel-resistant breast cancer cell lines and determined the function of ER alpha in the enhancement of paclitaxel resistance via the regulation of CD44 transcription. IBC down-regulated ER alpha and CD44 expression and thus inhibited tumour growth in paclitaxel-resistant xenograft models. Overall, our data demonstrated for the first time that IBC could decrease CD44 expression level via the ER alpha pathway and make ER+ breast cancer cells sensitive to paclitaxel treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据